Revenue
$1.5B
▼ 5.2% YoY
Net Income
$241.7M
▼ 34.2% YoY
EPS
$1.43
▼ 34.1% YoY
Cash
$388.6M
▲ 33.5% YoY
FY 2025 · As of 2025-12-31
Last 90 days
| Insider | Type | Date | Shares | Price | Value | |
|---|---|---|---|---|---|---|
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Vest | Sep 1, 2026 | 5.0K | $24.59 | $123K | Form 4 ↗ |
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sell | Sep 1, 2026 | 9.0K | $46.99 | $423K | Form 4 ↗ |
Nichols Christian Todd SVP, Chief Commercial Officer | Sell | Aug 17, 2026 | 6.9K | $49.19 | $340K | Form 4 ↗ |
Nichols Christian Todd SVP, Chief Commercial Officer | Sell | Aug 17, 2026 | 664 | $49.65 | $33K | Form 4 ↗ |
snyderman nancy lynn MD Director | Vest | Aug 3, 2026 | 27.9K | $46.72 | $1.31M | Form 4 ↗ |
snyderman nancy lynn MD Director | Vest | Aug 3, 2026 | 16.5K | $46.72 | $772K | Form 4 ↗ |
snyderman nancy lynn MD Director | Sell | Aug 3, 2026 | 44.5K | $50.35 | $2.24M | Form 4 ↗ |
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Vest | Aug 3, 2026 | 104 | $19.34 | $2K | Form 4 ↗ |
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Vest | Aug 3, 2026 | 4.9K | $24.59 | $120K | Form 4 ↗ |
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sell | Aug 3, 2026 | 9.0K | $48.58 | $437K | Form 4 ↗ |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sell | Aug 3, 2026 | 2.0K | $48.58 | $99K | Form 4 ↗ |
Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sell | Jul 6, 2026 | 2.0K | $54.03 | $110K | Form 4 ↗ |
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Vest | Jul 1, 2026 | 5.0K | $19.34 | $97K | Form 4 ↗ |
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sell | Jul 1, 2026 | 8.3K | $51.46 | $427K | Form 4 ↗ |
Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sell | Jul 1, 2026 | 700 | $52.13 | $36K | Form 4 ↗ |
Wright Christopher I Director | Sell | Jun 12, 2026 | 2.0K | $45.10 | $90K | Form 4 ↗ |